Description

Clopidogrel Coated Tablets 0.075 g. №30

Ingredients

Active ingredient: Clopidogrel 75mg.
Other ingredients: Microcrystalline cellulose, lactose monohydrate, colloidal anhydrous silica, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 6000.

Dosage

Adults: The usual dose is one tablet daily, taken orally with or without food, or as directed by a healthcare professional.

Indications

Clopidogrel tablets are indicated for the prevention of atherothrombotic events in patients with a history of recent myocardial infarction, recent stroke, or established peripheral arterial disease.

Contraindications

Do not use Clopidogrel tablets if you have an active pathological bleeding such as peptic ulcer or intracranial hemorrhage. Consult a healthcare provider before use if you have a history of liver or kidney disease.

Directions

Take Clopidogrel tablets exactly as prescribed by your doctor. Do not change the dose or stop taking the medication without medical advice.

Scientific Evidence

Clopidogrel is a widely studied antiplatelet medication that has shown significant efficacy in reducing cardiovascular events. Research published in the New England Journal of Medicine has demonstrated the benefits of clopidogrel in preventing recurrent cardiovascular events in high-risk patients.

Additional Information

It is important to inform your healthcare provider about all medications, supplements, and medical conditions before starting Clopidogrel therapy. In case of any unusual bleeding or bruising, seek immediate medical attention.

Pharmacological Effects:

Clopidogrel works by irreversibly inhibiting the P2Y12 adenosine diphosphate receptor on platelets, thereby preventing platelet activation and aggregation. This action reduces the risk of blood clot formation and subsequent cardiovascular events.

Clinical Trials:

In a comparative effectiveness study published in the Journal of the American Medical Association, clopidogrel was found to be as effective as aspirin in reducing the risk of cardiovascular events in patients with a history of atherothrombosis.